Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03939715
Other study ID # 1385925-1
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date April 5, 2020
Est. completion date May 5, 2022

Study information

Verified date January 2020
Source Colorado Pelvic Floor Consultants
Contact CATHERINE JAY
Phone 3039558059
Email cjay@surgone.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparing FDA-approved DermaPure with patient's own native tissue surgically for diagnosis of pelvic organ prolapse.


Description:

The investigator is comparing FDA-approved DermaPure with patient's own native tissue for the repair of pelvic organ prolapse. Please see below for detailed objectives and endpoints for our measuring parameters:

Objectives

Specific Aim #1:

To determine the relative safety and efficacy of anterior and multi-compartment vaginal wall prolapse repair augmented with decellularized human dermal allograft (DermaPure®) versus anterior and multi-compartment repair employing native tissue.

Specific Aim #2:

To evaluate bulge symptoms, quality of life, sexual function, and patient satisfaction

Our hypothesis is that pelvic organ prolapse repair augmented with DermaPure® will provide superior anatomic outcomes as compared to native tissue controls with a non-inferior safety profile.

Endpoints

Safety Endpoint #1:

The relative proportion of allograft, native tissue, and procedure-related SAE's at 12 months.

Safety Endpoint #2:

The relative proportion of allograft, native tissue, and procedure-related AE's of interest at 12 months, which include:

- Vaginal shortening

- Vaginal scarring or banding

- De novo vaginal bleeding

- Atypical vaginal discharge

- Fistula formation

- De novo dyspareunia

- Pelvic pain

- Peri-operative infection

- Vaginal infection

- UTI

- Neuromuscular disorder

- SUI (worsening or de novo)

- UUI (worsening or de novo)

- Difficulty emptying bladder (worsening or de novo)

- Graft exposure (into vagina)

- Graft erosion (into viscus)

Efficacy Endpoint #1:

The proportion of patients in each group at 36 months with prolapse of the target compartment beyond the hymen.

Efficacy Endpoint #2:

The proportion of patients in each group at 36 months with bulge symptoms attributable to the target compartment as determined by PFDI-20 question number 3 ("Does the participant usually have a bulge or something falling out that the participant can see or feel in the vaginal area") answering "yes" and >= 2 (responses of "somewhat", "moderately", or "quite a bit"). (Barber)

Efficacy Endpoint #3:

The proportion of patients in each group at 36 months requiring re-treatment for recurrent prolapse of the target compartment (to include surgery, physical therapy or pessary insertion).

Efficacy Endpoint #4:

Change in quality of life in each group from baseline to 36 months as measured by the PFDI-20 and the PFIQ-7. (Barber)

Efficacy Endpoint #5:

Change in sexual function in each group from baseline to 36 months as measured by the PISQ-IR. (Rogers)

Efficacy Endpoint #6:

Patient satisfaction in each group at 36 months as measured by the SSQ-8. (Haff)

Efficacy Endpoint #7:

Patient impression in each group at 36 months of postoperative improvement by the PGI-I (Srikrishna)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date May 5, 2022
Est. primary completion date May 5, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria:

- Subject is female

- Subject is at least 18 years of age

- Subject has prolapse of the anterior compartment beyond the hymen

- Subject reports bulge symptoms as defined in question 3 of the PFDI-20 with a response of 2 or higher ("somewhat", "moderately" or "quite a bit")

- Subject is willing and able to provide informed consent

- Subject is willing and able to comply with the follow-up protocol through 36 months

Exclusion criteria:

- Subject is pregnant or intends to become pregnant during the study

- Subject has untreated severe urogenital atrophy

- Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI), or tissue necrosis

- Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)

- Subject has had prior pelvic radiation therapy

- Subject has taken systemic steroids within the last month, or immunosuppressive or immunomodulatory treatment within the last 3 months (list attached)

- Subject has a history of poor wound healing with or without a diagnosis of connective tissue disease

- Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis

- Subject has uncontrolled diabetes mellitus (DM) as defined by a hemoglobin A1C < or = to 8% (Underwood, Ata)

- Subject has a known neurologic or medical condition that may effect of currently affects bladder function

- Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse (colpocleisis)

- Subject is not able to conform to the modified dorsal lithotomy position

- Subject is currently participating in or plans to participate in another pelvic organ prolapse related study during this study

- Subject has had previous prolapse repair with synthetic mesh in the anterior compartment

- Subject is planning to undergo a concomitant prolapse repair in a non-target compartment with anything other than native tissue or DermaPure®

- Subject is unable to be treated in the anterior compartment with DermaPure®

- Subject is desirous of a concomitant hysteropexy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
DermaPure®
Surgical intervention using DermaPure®
Procedure:
native tissue
Surgical intervention using native tissue

Locations

Country Name City State
United States Colorado Pelvic Floor Consultants Englewood Colorado

Sponsors (2)

Lead Sponsor Collaborator
Colorado Pelvic Floor Consultants Tissue Regenix Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety through AE and SAE assessments and percentage of incidences The relative proportion of allograft, native tissue, and procedure-related SAE's is assessed at 12 months, 24 months, and 36 months.
The relative proportion of allograft, native tissue, and procedure-related AE's of interest is assessed at 12 months, 24 months, and 36 months which include:
Vaginal shortening
Vaginal scarring or banding
De novo vaginal bleeding
Atypical vaginal discharge
Fistula formation
De novo dyspareunia
Pelvic pain
Peri-operative infection
Vaginal infection
UTI
Neuromuscular disorder
SUI (worsening or de novo)
UUI (worsening or de novo)
Difficulty emptying bladder (worsening or de novo)
Graft exposure (into vagina)
Graft erosion (into viscus)
3 years
Primary Quality of Life through the administration of questionnaires, analyzed at the end of the study as % of patients that are satisfied or above satisfied The proportion of patients in each group at 36 months with bulge symptoms attributable to the target compartment as determined by PFDI-20 question number 3 ("Do you usually have a bulge or something falling out that you can see or feel in the vaginal area") answering "yes" and >= 2 (responses of "somewhat", "moderately", or "quite a bit"). (Barber) Change in quality of life in each group from baseline to 36 months as measured by the PFDI-20 and the PFIQ-7. (Barber) 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05422209 - The Influence of Simultaneous Posterior Colporrhaphy and Perineoplasty on the Efficiency and Safety of Mesh-augmented Sacrospinal Fixation (Apical Sling) in Advanced POP Repair. N/A
Active, not recruiting NCT05420831 - Comparison of Vaginal and Laparoscopic Apical Fixation Techniques for Pelvic Organ Prolapse Treatment N/A
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT06126328 - Materna Prep Study Phase II Phase 2
Recruiting NCT05542836 - EVeRLAST 2-Year Follow-Up
Recruiting NCT05918367 - Multicenter Ventral Mesh Rectopexy Registry Collaborative
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Completed NCT06268782 - The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women N/A
Recruiting NCT03146195 - The 3D Reconstruction Research of Pelvic Organ Prolapse Disease N/A
Recruiting NCT02919852 - Laparoscopic Retrovesical Colpopectinopexia N/A
Completed NCT02925585 - Vaginal Tactile Imaging for Pelvic Floor Prolapse
Not yet recruiting NCT02536001 - Prospective Randomized Study to Compare Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes N/A
Recruiting NCT02113969 - Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol N/A
Completed NCT02383199 - Polypropylene Mesh in Prolapse Surgery N/A
Terminated NCT01673360 - Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices N/A
Withdrawn NCT01530191 - Factors Affecting Perioperative Outcomes N/A
Completed NCT01842464 - Sacro-Spinous Ligaments Anterior Apical Anchoring N/A
Completed NCT01320631 - Male Sexual Experience and Its Impact on Quality of Life Before and After Their Sexual Partners Undergo Polypropylene Mesh Augmented Pelvic Floor Reconstruction N/A
Completed NCT00581412 - Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates N/A